Jyoti D Patel1, Mark A Socinski, Edward B Garon, Craig H Reynolds, David R Spigel, Mark R Olsen, Robert C Hermann, Robert M Jotte, Thaddeus Beck, Donald A Richards, Susan C Guba, Jingyi Liu, Bente Frimodt-Moller, William J John, Coleman K Obasaju, Eduardo J Pennella, Philip Bonomi, Ramaswamy Govindan. 1. Jyoti D. Patel, Northwestern University; Philip Bonomi, Rush University Medical Center, Chicago, IL; Mark A. Socinski, University of Pittsburgh, Pittsburgh, PA; Edward B. Garon, University of California at Los Angeles, Los Angeles, CA; Craig H. Reynolds, US Oncology Research, Ocala, FL; David R. Spigel, Sarah Cannon Research Institute-Tennessee Oncology, Nashville, TN; Mark R. Olsen, Tulsa Cancer Institute, Tulsa, OK; Robert C. Hermann, Northwest Georgia Oncology Centers, Marietta, GA; Robert M. Jotte, Rocky Mountain Cancer Centers, Denver, CO; Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Donald A. Richards, US Oncology Research, Tyler, TX; Susan C. Guba, Jingyi Liu, Bente Frimodt-Moller, and William J. John, Eli Lilly, Indianapolis, IN; Coleman K. Obasaju and Eduardo J. Pennella, Lilly USA, Indianapolis, IN; and Ramaswamy Govindan, Washington University School of Medicine, St. Louis, MO.
Abstract
PURPOSE: PointBreak (A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer) compared the efficacy and safety of pemetrexed (Pem) plus carboplatin (C) plus bevacizumab (Bev) followed by pemetrexed plus bevacizumab (PemCBev) with paclitaxel (Pac) plus carboplatin (C) plus bevacizumab (Bev) followed by bevacizumab (PacCBev) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Patients with previously untreated stage IIIB or IV nonsquamous NSCLC and Eastern Cooperative Oncology Group performance status of 0 to 1 were randomly assigned to receive pemetrexed 500 mg/m(2) or paclitaxel 200 mg/m(2) combined with carboplatin area under the curve 6 and bevacizumab 15 mg/kg every 3 weeks for up to four cycles. Eligible patients received maintenance until disease progression: pemetrexed plus bevacizumab (for the PemCBev group) or bevacizumab (for the PacCBev group). The primary end point of this superiority study was overall survival (OS). RESULTS: Patients were randomly assigned to PemCBev (n = 472) or PacCBev (n = 467). For PemCBev versus PacCBev, OS hazard ratio (HR) was 1.00 (median OS, 12.6 v 13.4 months; P = .949); progression-free survival (PFS) HR was 0.83 (median PFS, 6.0 v 5.6 months; P = .012); overall response rate was 34.1% versus 33.0%; and disease control rate was 65.9% versus 69.8%. Significantly more study drug-related grade 3 or 4 anemia (14.5% v 2.7%), thrombocytopenia (23.3% v 5.6%), and fatigue (10.9% v 5.0%) occurred with PemCBev; significantly more grade 3 or 4 neutropenia (40.6% v 25.8%), febrile neutropenia (4.1% v 1.4%), sensory neuropathy (4.1% v 0%), and alopecia (grade 1 or 2; 36.8% v 6.6%) occurred with PacCBev. CONCLUSION: OS did not improve with the PemCBev regimen compared with the PacCBev regimen, although PFS was significantly improved with PemCBev. Toxicity profiles differed; both regimens demonstrated tolerability.
RCT Entities:
PURPOSE: PointBreak (A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer) compared the efficacy and safety of pemetrexed (Pem) plus carboplatin (C) plus bevacizumab (Bev) followed by pemetrexed plus bevacizumab (PemCBev) with paclitaxel (Pac) plus carboplatin (C) plus bevacizumab (Bev) followed by bevacizumab (PacCBev) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Patients with previously untreated stage IIIB or IV nonsquamous NSCLC and Eastern Cooperative Oncology Group performance status of 0 to 1 were randomly assigned to receive pemetrexed 500 mg/m(2) or paclitaxel 200 mg/m(2) combined with carboplatin area under the curve 6 and bevacizumab 15 mg/kg every 3 weeks for up to four cycles. Eligible patients received maintenance until disease progression: pemetrexed plus bevacizumab (for the PemCBev group) or bevacizumab (for the PacCBev group). The primary end point of this superiority study was overall survival (OS). RESULTS:Patients were randomly assigned to PemCBev (n = 472) or PacCBev (n = 467). For PemCBev versus PacCBev, OS hazard ratio (HR) was 1.00 (median OS, 12.6 v 13.4 months; P = .949); progression-free survival (PFS) HR was 0.83 (median PFS, 6.0 v 5.6 months; P = .012); overall response rate was 34.1% versus 33.0%; and disease control rate was 65.9% versus 69.8%. Significantly more study drug-related grade 3 or 4 anemia (14.5% v 2.7%), thrombocytopenia (23.3% v 5.6%), and fatigue (10.9% v 5.0%) occurred with PemCBev; significantly more grade 3 or 4 neutropenia (40.6% v 25.8%), febrile neutropenia (4.1% v 1.4%), sensory neuropathy (4.1% v 0%), and alopecia (grade 1 or 2; 36.8% v 6.6%) occurred with PacCBev. CONCLUSION:OS did not improve with the PemCBev regimen compared with the PacCBev regimen, although PFS was significantly improved with PemCBev. Toxicity profiles differed; both regimens demonstrated tolerability.
Authors: H Ozer; J O Armitage; C L Bennett; J Crawford; G D Demetri; P A Pizzo; C A Schiffer; T J Smith; G Somlo; J C Wade; J L Wade; R J Winn; A J Wozniak; M R Somerfield Journal: J Clin Oncol Date: 2000-10-15 Impact factor: 44.544
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: C Sandomenico; R Costanzo; G Carillio; M C Piccirillo; A Montanino; M Di Maio; G Rocco; N Normanno; F Perrone; A Morabito Journal: Curr Med Chem Date: 2012 Impact factor: 4.530
Authors: Joan H Schiller; David Harrington; Chandra P Belani; Corey Langer; Alan Sandler; James Krook; Junming Zhu; David H Johnson Journal: N Engl J Med Date: 2002-01-10 Impact factor: 91.245
Authors: Christopher G Azzoli; Sarah Temin; Timothy Aliff; Sherman Baker; Julie Brahmer; David H Johnson; Janessa L Laskin; Gregory Masters; Daniel Milton; Luke Nordquist; William Pao; David G Pfister; Steven Piantadosi; Joan H Schiller; Reily Smith; Thomas J Smith; John R Strawn; David Trent; Giuseppe Giaccone Journal: J Clin Oncol Date: 2011-09-06 Impact factor: 44.544
Authors: Jean-Louis Pujol; Sofia Paul; Nadia Chouaki; Patrick Peterson; Patti Moore; Donald A Berry; Marc Salzberg Journal: J Thorac Oncol Date: 2007-05 Impact factor: 15.609
Authors: Giorgio Vittorio Scagliotti; Purvish Parikh; Joachim von Pawel; Bonne Biesma; Johan Vansteenkiste; Christian Manegold; Piotr Serwatowski; Ulrich Gatzemeier; Raghunadharao Digumarti; Mauro Zukin; Jin S Lee; Anders Mellemgaard; Keunchil Park; Shehkar Patil; Janusz Rolski; Tuncay Goksel; Filippo de Marinis; Lorinda Simms; Katherine P Sugarman; David Gandara Journal: J Clin Oncol Date: 2008-05-27 Impact factor: 44.544
Authors: Giorgio V Scagliotti; Keunchil Park; Shekar Patil; Janusz Rolski; Tuncay Goksel; Renato Martins; Steven J M Gans; Carla Visseren-Grul; Patrick Peterson Journal: Eur J Cancer Date: 2009-05-25 Impact factor: 9.162
Authors: Jyoti D Patel; Thomas A Hensing; Alfred Rademaker; Eric M Hart; Matthew G Blum; Daniel T Milton; Philip D Bonomi Journal: J Clin Oncol Date: 2009-05-11 Impact factor: 44.544
Authors: Grace K Dy; Julian R Molina; Yingwei Qi; Rafat Ansari; Sachdev Thomas; Helen J Ross; Gamini Soori; Daniel Anderson; Marie Christine Aubry; Jeffrey Meyers; Araba A Adjei; Sumithra Mandrekar; Alex A Adjei Journal: J Thorac Oncol Date: 2014-08 Impact factor: 15.609
Authors: Scott Gettinger; Naiyer A Rizvi; Laura Q Chow; Hossein Borghaei; Julie Brahmer; Neal Ready; David E Gerber; Frances A Shepherd; Scott Antonia; Jonathan W Goldman; Rosalyn A Juergens; Scott A Laurie; Faith E Nathan; Yun Shen; Christopher T Harbison; Matthew D Hellmann Journal: J Clin Oncol Date: 2016-06-27 Impact factor: 44.544
Authors: Naiyer A Rizvi; Matthew D Hellmann; Julie R Brahmer; Rosalyn A Juergens; Hossein Borghaei; Scott Gettinger; Laura Q Chow; David E Gerber; Scott A Laurie; Jonathan W Goldman; Frances A Shepherd; Allen C Chen; Yun Shen; Faith E Nathan; Christopher T Harbison; Scott Antonia Journal: J Clin Oncol Date: 2016-06-27 Impact factor: 44.544
Authors: Suresh S Ramalingam; Suzanne E Dahlberg; Chandra P Belani; Joel N Saltzman; Nathan A Pennell; Gopakumar S Nambudiri; John C McCann; Jerome D Winegarden; Mohammed A Kassem; Mohamed K Mohamed; Jan M Rothman; Alan P Lyss; Leora Horn; Thomas E Stinchcombe; Joan H Schiller Journal: J Clin Oncol Date: 2019-07-30 Impact factor: 44.544